LadyBiotic-UTH 60 Veggie Caps Vinco

LadyBiotic-UTH 60 Veggie Caps Vinco
Item# 739930275607
$31.90

Vinco's LadyBiotic® UTH, contains Cran-Gyn® DDS®, which is a patent-pending triple action formula that contains DDS® Probiotics, Cranberry Juice Extract, and natural D-Mannose. LadyBiotic® UTH is specifically formulated to address unique feminine considerations including urinary tract health, digestive health, immune function, and yeast management. No Wheat, Eggs, Yeast, Corn, Soy, Gluten, Artificial Colors or Preservatives. NON-GMO and Vegan Laboratory tested to meet strict quality control.

Supplement Facts: Serving Size: 2 Vegetarian Capsules, Servings per Container: 30

Amount per Serving %DV

A proprietary blend containing (1g) † Cranberry Juice Concentrate, Natural D-Mannose, Lactobacillus acidophilus DDS-1®, Bifidobacterium longum, Bifidobacterium bifidum, Bifidobacterium lactis, and Fructooligosaccharide, which provide: 5 Billion CFU (Colony Forming Units)

* Daily Value (DV) not established DV is based on a 2,000 calorie diet Other Ingredients: Vegetable Cellulose, Rice Maltodextrin, Vegetable Magnesium Stearate, Magnesium Hydroxide, Tricalcium Phosphate

Vinco’s LadyBiotic® UTH is formulated to address the unique health needs of women. LadyBiotic® UTH targets urinary tract health, digestive health, immune function and management of healthy yeast levels.

Urinary Tract Infections Urinary tract infections (UTI) are particularly prevalent in women with over 50% of women reporting UTIs at some time in their life and over 30% suffering from recurrent problems. UTIs result in over 10 million doctor visits per year at a cost of over $3.5 billion. It is estimated that over 11 million women with UTIs in the US will be treated with antibiotics. Antibiotic treatment can often result in a secondary yeast infection that requires anti-fungal treatment. The primary cause of lower urinary tract infections is a common fecal bacteria, E. coli. (Approx 90% of cases).

UTIs occur when the bacteria enter the urethra and bladder causing infection, severe irritation and inflammation. In the past ten years, there have been many studies that demonstrate that lectins on the bacterial surfaces may be involved in starting the infection by assisting in bacterial adherence to epithelial cells. Bacterial adherence appears to be one of the prerequisites for the development of UTIs.

Probiotics - Broad Spectrum Application For UTI Studies indicate that women with no history of UTI have high numbers of Lactobacilli present in the urogenital area and that patients with a history of recurrent UTIs have severely depleted numbers of Lactobacilli. Researchers indicate that the Lactobacilli provide a bacterial barrier able to interfere with the ability of pathogens to colonize the vagina and reduce the risk of ascension into the bladder.

In a study on prevention of UTI, a weekly vaginal suppository containing L. rhamnosus GR-1 and L. fermentum B-54 for one year showed significant reduction in UTI during the Lactobacillus use (from 6 times per year to <1.6 times per year). A pilot study using vaginal suppositories of hydrogen-peroxide producing Lactobacillus crispatus demonstrated reduction in UTI recurrence. Lactobacilli and the hydrogen peroxide they produce are emerging as essential components of a healthy microflora environment. Hydrogen peroxide is toxic to many microorganisms at concentrations that are typical in vaginal fluid and thus provide intrinsic protective mechanism in the vagina.

Another possible mechanism of action involves production of bacteriocins by Lactobacilli. Lactobacillus acidophilus DDS®-1 produces a natural antibacterial substance called acidophilin that has demonstrated activity against several strains of bacteria including E. coli. In a case study of L. acidophilus DDS®-1 with two billion viable organisms, there were positive results in prevention of recurrent UTIs.

Irritable Bowel Syndrome One of the most prevalent digestive conditions affecting both men and women, but significantly more women, is irritable bowel syndrome (IBS). It affects over 20% of the population in Western countries with a female to male ratio of 2-2.5:1. IBS remains to be a clinically defined illness and traditionally, is a diagnosis of exclusion. Although many pathophysiologic factors have been implicated in IBS, recently, researchers have considered food intolerance imbalance of the intestinal microflora and colonic malfermentation as potential factors responsible for IBS. Current treatment options for IBS are thought of as unsatisfactory, and probiotics are on promising therapeutic option.

A promising application is to use probiotic bacteria that interact with the host epithelium to resolve inflammation and preserve barrier function. Currently most commonly studied probiotics are lactic acid bacteria (LAB). Some probiotics including Bifidobacterium and Lactobacillus species have been shown to relieve symptoms.

Recently, researchers conducted a multi-patient case study using a probiotic blend (Multi-Flora Plus) containing L. acidophilus DDS-1, B. longum, B. bifidum, and B. lactis at a potency of 12 billion CFU/g. After treating 25 patients for 8 weeks, the researchers demonstrated a significant decrease in symptom severity

Bacterial Vaginosis (BV) and Vulvovaginal Candidiasis (VVC) BV and VVC are the most prevalent vaginal infections worldwide. BV causes up to 50% of vaginal infections and is accompanied by a significant reduction in lactobacilli.

VVC affects up to 75% of women at least once in their lives. The total annual cost (in 1995) for dealing with VVC was estimated at $1.8 billion. Although the pathogenesis of VVC remains controversial, it seems that the balance between the microorganisms in the vaginal microbiota is a factor that influences overgrowth of Candida. Antibiotic therapy, spermicide use, oral contraceptives, estrogen therapy, diabetes, tight clothing and frequent sexual intercourse are all factors that increase the risk of development of VVC.

Lactobacilli modulate the vaginal microbiota by different mechanisms such as: (1)augo-aggregation, (2)production of lactic acid, hydrogen peroxide, bacteriocins, biosurfactants, (3)co-aggregation with pathogenic microorganisms and (4)adhesion to epithelial cells.

Probiotics - Broad Spectrum Application For Bacterial Vaginosis (BV) In BV, anaerobic bacteria multiply in large numbers and form biofilms on the epithelium which results in elevated pH and production of sialidase, hemolysins and factors that induce inflammatory cytokines. One trial of 64 women taking oral Lactobacilli led to a significant reduction of uropathogens and yeast in the vagina. Hydrogen peroxide producing Lactobacilli are believed to be important in conferring protection. A study of 290 subjects showed that females colonized by H2O2 producing Lactobacilli, vaginally and rectally, had a reduced risk of vaginal infection. Lactobacillus DDS®-1 produces hydrogen peroxide in addition to a potent bacteriocin.

Probiotics - Broad Spectrum Application For Vulvovaginal Candidiasis (VVC) Lactobacilli exert a protective effect against VVC by several mechanisms. The first is adherence to the vaginal epithelium leading to intensive surface colonization and biofilm formation. The subsequent production of active metabolites including acidic products, bacteriocins and hydrogen peroxide further inhibit the growth of Candida. The third mechanism involves co-aggregation of Lactobacillus and Candida which creates a microenvironment around the pathogen with a higher concentration of inhibitory substances and blocking the dissemination of pathogens to tissue receptors.

Cranberry Extract and UTI’s Both in vitro and in vivo tests using cranberry for UTI in animals has been effective. It seems that cranberry inhibits the adhesion of type 1 and P-fimbriated uropathogenic E. coli to the uroepithelium, preventing colonization and subsequent infection. E. coli with type 1 fimbriae are mannose sensitive and P-fimbriated E. coli are mannose resistant. The specific components of this anti-adhesion quality have been difficult to identify but there is emerging evidence that the anthocyanidin / proanthocyanidin fractions are involved since they have strong anti-adhesion properties.

Many studies have been conducted using cranberry to prevent recurrence of UTIs. In one meta-analysis, the recurrences were reduced by approximately 35%. There appears to be little difference whether the cranberry is in juice or tablet form.

Mannose Therapy and UTI’s Tamm-Horsfall Protein (THP) is a mucoprotein found in the urinary tract. It is the most abundant protein involved in innate urinary defense. THP deficiency predisposes individuals to bladder infection by type 1- fimbriated E. coli. Deficiency in THP does not enhance the ability of P-fimbriated E. coli to colonize the bladder. New studies show that mannose can bond to THP and serve as a receptor to type 1-fimbriated E. coli thus preventing them from adhering to uroplakin receptors on the uroepithelial surface. The ability of D-Mannose to inhibit type-1 fimbriated E. coli is the foundation for its use by sufferers of UTI infection.

References 1. Foxman B, Barlow R, D’Arcy H, Gillespie B, Sobel JD. Urinary tract infection: self-reported incidence and associated costs. Ann Edidemiol 2000; 10:509-15.

2. Litwin MS, Saigal CS, editors. Urologic Diseases in America. NIH publication 07-5512: 3-7. DHHS, PHS, NIH, NIDDK. Washington DC GPO; 2007.

3. www.hmc.psu.edu/healthinfo/uz/uti.htm. Accessed 12/23/2010.

4. Bar-Shavit Z, Goldman R, Ofek I et. al. Mannose Binding Activity of Escherichia coli: a Determinant of Attachment and Ingestion of the Bacteria by Macrophages. Infection and Immunity 1980; 29(2): 417-424.

5. Howell AB, Vorsa N, Marderosian AD, Foo LY. Inhibition of the adherence of p-fimbrated Eschericha coli to uroepithelial-cell surfaces by proanthocyanidin extracts from cranberries. New Eng Jnl Med 1998; 339: 1085.

6. Adeyemo MA, Spiegel MR, Chang L. Meta-analysis: Do Irritable Bowel Syndrome Symptoms Vary Between Men and Women? Aliment Pharm & Therap. 2010;32(6(:738-755.

7. Hunter, JO, Alun Jones, V. Food and the Gut;1985. http://jn.nutrition. org/cgi/reprint/117/6/1160.pdf.

8. King, TS, Elia M, Hunter JO. Lancet 1998 Oct 10;352(9235):1187-9. http://www.ncbi.nlm.nih.gov/pubmed/9777836.

9. Rolfe RD. The role of probiotic cultures in the control of gastrointestinal health. J Nutr 2000; 130:396S-402S.

10. Borowiec AM, Fedorak RN. The role of probiotics in management of irritable bowel syndrome. Curr Gastroenterol Rep 2007;9:393-400.

11. Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrheapredominant irritable bowel syndrome. Aliment Pharmacol Ther 2003;17:895-904.

12. O’Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128: 541-51.

13. Nagala R, Routray C. Clinical Case Study: Multispecies Probiotic Supplement Minimizes Symptoms of Irritable Bowel Syndrome. 2010. Case Study.

14. Reid G, Bruce AW, Fraser N, Heinemann C, Owen J, Henning B. Oral probiotics can resolve urogenital infections. FEMS Immunol Med Microbiol 2001;30:49-52.

15. Eschenback, DA, Hillier S, Chrichlow, C, Stevens, C, DeRouen T, Holmes KK. Diagnosis and clinical manifestations of bacterial vaginosis. Am J Obstet Gynecol1988; 158:819-828.

16. Sobel, JD Vulvovaginal candidiasis. Lancet 2007; 369:1961-1971.

17. Falagas, ME, Betsi, GI and Athanasiou, S. Probiotics for prevention of recurrent vulvovaginal candidiasis: a review. J Antimicro Chemother 2006; 58:266-272.

18. Jeavons H. Prevention and treatment of vulvovaginal candidiasis using exogenous Lactobacillus. J Obstet Gynecol Neonatal Nurs 2003;32:287-96.

19. Lepargneur, JP, Rousseau, V. Protective role of the Doderlein flora. APMIS 2002;113:305-316.

20. Reid, G. Probiotic agents to protect the urogenital tract against infection. Am J Clin Nutr 2001; 73:437-443.

21. Strus M, Kucharska A, Kukla G, Brzychezy-Wloch M, Maresz, K, Heczko PB. The in vitro activity of vaginal Lactobacillus with probiotic properties against Candida Infect Dis Obstet Gynecol 2005; 13(2):69-75.

22. Howell AB, Reed JD, Krueger CG, Winterbottom R, Cunningham DG, Leahy M. A-type cranberry proanthocyanidins and uropathogenic bacterial anti-adhesionactivity. Phytochemistry 2005Sept;66(18):2281-91.

23. Guay DR. Cranberry and urinary tract infections. Drugs 2009; 69(7):775-807.

24. Mo L, Zhu XH, Huang HY, et al. Ablation of the Tamm-Horsfall protein gene increases susceptility of mice to bladder colonization by type 1-fimbriated Escherichia coli. Am J Physiol Renal Physiol 2004; 286(4):F795-802. Epub 2003 Dec 9.

25. Bruce AW, Chadwick P, Hassan A, VanCott GF. Recurrent urethritis in women. Can Med Assoc J 1973; 108:973-76.

26. Bruce AW, Reid G. Probiotics and the urologist. Can J Urol 2003; 10(2):1785-1789.

27. Reid G, Bruce AW and Taylor, M. Instillation of Lactobacillus and stimulation of indigenous organisms to prevent recurrence of urinary tract infections. Microecolo Ther 1995; 23:32-45.

28. Uehara S, Monden K, Nomoto K, Seno Y, Kariyama R, Kumon H. A pilot study evaluating the safety and effectiveness of Lactobacillus vaginal suppositories in patients with recurrent urinary tract infection. Int J Antimicro Agts 2006; 28S:S30-S34.

29. Eschenbach DA, Davick PR, Williams BL, et al. Prevalence of hydrogen peroxide-producing Lactobacillus species in normal women and women with bacterial vaginosis. J Clin Microbiol 1989;27:251-256.

30. Shahani KM, Vakil JR, Kilara A. Natural antibiotic activity of L. acidophilus and bulgaricus. Cultural conditions for the production of antibiosis. Cult Dairy Prod J 1976;11:14-17.

31. Gerasimov SV. Probiotic prophylaxis in pediatric recurrent urinary tract infection. Clin Pediatr 2004;43:95-8.

32. Cauci S, Guaschino S, De Aloysio D, Driussi S, De Santo D, SPenacchioni P, Quadrifoglio F. Interrelationships of interleukin-8 with interleukin-1 beta and neutrophils in vaginal fluid of healthy and bacterial vaginosis positive women. Mol Hum Reprod 2003; 9(1)53-58.

33. Reid G, Charbonneau D, Erb J, Kochanowski B, Beuerman D, Poehner R, Bruce AW. Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized , placebo-controlled trial in 64 healthy women. 2003. FEMS Immunol Med Microbiol; 35(2):131-134.

34. Antonio MA, Rabe LK, Hillier SL. Colonization of the rectum by Lactobacillus species and decreased risk of bacterial vaginosis. 2005. J Infect Dis; 192(3):394-398.

35. Attaie R, Whalen PJ, Shahani KM, Amer MA. Inhibition of growth of S. aureus during production of acidophilus yogurt. 1987. J. Food Protect; 50:224-8.

36. Strus M, Marewicz E, Kukla G, et al. Surface properties of Lactobacillus strains of human origin. Microb Ecol Health Dis 2001;13:240-245.

37. Klebanoff SJ, Hillier SL, Eschenbach DA, Waltersdorph AM. Control of the microbial flora of the vagina by H2O2-generating lactobacilli. J Infect Dis 1991;164:94-100

38. McGoarty JA. Probiotic use of lactobacilli in the human female urogenital tract. FEMS Immunol Med Microbiol 1993;6:251-264.

39. Mastomarino P, Brigidi P, Macchia S, Maggi L, Pirovano, F, Trinchieri, V, Conte U, Matteuzzi D. Characterization and selection of vaginal Lactobacillus strains for the preparation of vaginal tablets. J Appl Microbiol (2002);93:884-893.